Johnson & Johnson (JNJ) announced a definitive agreement with Swiss biotech Numab Therapeutics to acquire global rights to NM26, a phase II-ready bispecific antibody for atopic dermatitis (“AD”). To execute the deal, Numab Therapeutics will spin off its wholly-owned subsidiary called Yellow Jersey Therapeutics, which holds NM26 rights, to its shareholders. J&J will acquire Yellow Jersey Therapeutics from Numab’s shareholders for a purchase price of $1.25 billion in cash.AD is a common inflammatory disease c ...

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab's pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Numab), a clin ...

In the latest trading session, Johnson & Johnson (JNJ) closed at $146.97, marking a -1.82% move from the previous day. This move lagged the S&P 500's daily gain of 0.7%. On the other hand, the Dow registered a gain of 0.01%, and the technology-centric Nasdaq increased by 1.1%.The the stock of world's biggest maker of health care products has risen by 1.96% in the past month, lagging the Medical sector's gain of 3.27% and the S&P 500's gain of 4.03%.Market participants will be closely following the financial ...

In today’s uncertain market, securing investment returns is essential to protect your wealth from future downturns. Three businesses stand out as islands of stability amid geopolitical unrest and economic uncertainty. These massive companies in the industry provide defensive equities that are attractive buys for investors looking to strengthen their holdings. The first one shows substantial expansion in margins and profit growth. As a fundamental requirement, its diverse range of medical equipment and medic ...

NEW YORK — A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company’s bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.Five plaintiffs who seek to represent over 50,000 people who have sued J&J over its talc products filed the proposed class action in New Jersey federal court. 3 J&J has said that its baby powder an ...

Investors often look to safe-haven equities for stability and reliable returns during uncertain economic times. Here are seven strong afe-haven stocks to buy that offer encouraging chances to endure financial disasters.To begin with, the first has had notable growth in its markets, especially in the United States, due to its well-received product introductions and market penetration. The second one sustains its market leadership through effective operations and strong returns to shareholders while deliverin ...

Johnson & Johnson is a high-quality dividend stock.Johnson & Johnson (JNJ -0.14%) is dividend royalty. The healthcare behemoth has increased its dividend payment for 62 straight years. That puts it in the elite group of Dividend Kings, companies with 50 or more years of consecutive annual dividend growth.The healthcare stock also stands out for its higher dividend yield. With a nearly 3.3% forward dividend yield, an investment in Johnson & Johnson would generate more than double the dividend income of a sim ...

Johnson & Johnson (JNJ) announced that it has entered into a definitive agreement to acquire private biotech Proteologix for $850 million in cash, with the potential for an additional milestone payment.The transaction is expected to be closed in mid-2024, subject to customary closing conditions.With the latest acquisition, JNJ is looking to boost its dermatology portfolio with an aim to address significant unmet needs in atopic dermatitis (AD), also known as eczema.Proteologix is engaged in developing bispe ...

A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 5.5% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q1 Earnings Beat Estimates, Sales Miss ...

Johnson & Johnson (NYSE:JNJ) RBC Capital Markets Global Healthcare Conference May 15, 2024 11:00 AM ET Company Participants Timothy Schmid - Executive Vice President and Worldwide Chairman of MedTech Conference Call Participants Shagun Singh - RBC Capital Markets Shagun Singh We will get started. Hello everyone, and welcome to the 2024 RBC Capital Global Healthcare Conference. I’m Shagun Singh, Senior Medical Device Analyst at RBC. And I’m very pleased to have Johnson & Johnson here with us again this year. ...